News
Donnelley Financial Solutions (NYSE: DFIN) is slated to release its earnings on Tuesday before the market opens. The previous quarter ended with revenues of $175.3 million, a 2.3 % decline year‑over‑year, yet the company beat analysts’ revenue expectations by 3.3 %. Despite this, DFIN has missed Wall Street revenue estimates five times in the past...
17/02/2026 | Donnelley Financial Solutions, Inc.
United Parks & Resorts (PRKS) has reported continued struggles in visitor performance relative to industry peers, a key driver of its revenue growth. Over the past two years, the company’s free cash flow margin has declined to 11.8%, constraining capital available for expansion and share repurchase activity. The firm’s current investment decisions...
17/02/2026 | United Parks & Resorts Inc.
Krispy Kreme (DNUT) trades at $2.97 per share and is one of the stocks highlighted among those priced below $10. The fast‑food chain’s earnings per share have fallen over the last four years, prompting concerns that its long‑term growth prospects are weak. Cash burn remains high, and the company’s short cash runway increases the probability of a ca...
17/02/2026 | Krispy Kreme, Inc.
Overall, the firm’s commercial traction with Casgevy, combined with a growing pipeline and a projected lift in 2026 revenue, remains the central narrative driving investor interest, while the sizable quarterly and annual losses, reliance on Vertex, and the recent equity issuance temper expectations of short‑term profitability.
16/02/2026 | CRISPR Therapeutics AG
CRISPR Therapeutics continues to broaden its pipeline through collaborations with Vertex and Sirius Therapeutics. New candidates include CTX310 (cardiovascular), CTX611 (thromboembolic), a refractory hypertension therapy, treatments for alpha‑1 antitrypsin deficiency affecting lung and liver disease, and several autoimmune disease indications. The...
16/02/2026 | CRISPR Therapeutics AG
Casgevy sales in 2025 totaled $116 million, surpassing Vertex’s target of approximately $100 million, a performance that prompted Needham to lift its price target on CRISPR Therapeutics from $80 to $82 while maintaining a Buy rating. The firm’s share price has declined 6.7% over the past 30 days, sits about 37% below analyst targets, and trades rou...
16/02/2026 | CRISPR Therapeutics AG
CRISPR Therapeutics has advanced the commercialization of its FDA‑approved gene‑editing therapy Casgevy for sickle cell disease and beta‑thalassemia, securing reimbursement and access agreements that cover the majority of eligible U.S. patients and outlining expansions into Europe and the Middle East. In its most recent quarter, the company reporte...
16/02/2026 | CRISPR Therapeutics AG
Rexel’s share price has risen 44.9 % over the past year, but it fell 3.5 % in the last seven days. The company scores 2 of 6 on Simply Wall St’s valuation screen, indicating undervaluation on two of six criteria. A discounted‑cash‑flow (DCF) analysis shows Rexel may be overvalued by 36.9 %, with an intrinsic value of €26.49 per share versus the rec...
16/02/2026 | Rexel S.A.
Scorpio Tankers Inc. (STNG) announced it will raise its dividend to $0.45 per share effective March 20, yielding 2.6%, below the industry average. The company has maintained a history of dividend payments, though recent cuts have indicated a declining trend of roughly 9.7% per year since 2016. In contrast, EPS has grown 34% annually over the past f...
16/02/2026 | Scorpio Tankers Inc.
Analyst coverage reflects a mixed outlook. Benchmark lowered its price target for Maplebear from $60 to $53 on February 10, 2026, yet retained a “Buy” rating, citing current multiples and secular tailwinds. Needham increased its target from $50 to $55 on February 13, 2026, also maintaining a “Buy” stance. Daniel Sundheim’s portfolio includes approx...
16/02/2026 | Maplebear Inc.